NEW YORK, Jan 10 – Qiagen Genomics said Wednesday that it has entered into three new licensing agreements involving its Masscode technology for high-throughput SNP genotyping.

The agreements, announced separately, involve Agilent Technologies, Japan’s Daiichi Pharmaceutical subsidiary of Daiichi Pure Chemicals (DPC), and the University of Washington School of Pharmacy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.